Medtronic plc (MDT) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter h...
Medtronic plc (MDT) currently trades at a P/E ratio of 23.17 (historical range: 20.58–46.00, median: 26.49), placing it at the 12th percentile — cheap relative to its history, P/S ratio of 3.23 (range: 2.68–5.65, 18th percentile — cheap relative to its history), EV/EBITDA of 20.76 (range: 16.69–41.53, 13th percentile).
Medtronic plc trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 23.17 | 26.49 | 12th | cheap relative to its history |
| P/S Ratio | 3.23 | 3.51 | 18th | cheap relative to its history |
| EV/EBITDA | 20.76 | 23.15 | 13th | cheap relative to its history |
| FCF Yield | 5.06% | 4.44% | 86th | cheap relative to its history |
Medtronic plc (MDT) Valuation & P/E History
Medtronic plc (MDT) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry currently trading at $94.80 with a market capitalization of $121.3 billion. This page provides historical valuation analysis for MDT based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 23.17 is below the historical median of 26.49, placing MDT at the 12th percentile of its valuation range. The P/S ratio of 3.23 compares to a median of 3.51.
MDT Valuation Metrics & Historical Range
The valuation table above shows Medtronic plc's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether MDT is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests MDT is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Medtronic plc.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is MDT Overvalued or Undervalued?
Medtronic plc trades well below its historical valuation range across most metrics. The overall valuation percentile of 14 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive MDT is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full MDT analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.MDT trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.